GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion

All NewsMay 14, 2025

GSK acquires Boston Pharmaceuticals’ efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent